Cancer

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…

4 weeks ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell”…

4 weeks ago

Parrish Board approves $25 million dollar technology investment for advanced electronic system to further improve patient and family care

TITUSVILLE, Fla., Jan. 13, 2026 /PRNewswire/ -- Patients of Parrish Medical Center and Parrish Healthcare will see a series of benefits…

4 weeks ago

RISA Labs Closes $11.1M Series A to Scale AI Operating System for Oncology Nationwide

PALO ALTO, Calif., Jan. 13, 2026 /PRNewswire/ -- RISA Labs, a company pioneering an AI operating system for oncology, today…

4 weeks ago

The Mark Foundation for Cancer Research Announces 2026 Emerging Leader Awards, Committing $3.75 Million to Next-Generation Oncology Breakthroughs

Since 2018, more than $40 million has been granted to support outstanding cancer research projects by early-career scientistsNEW YORK, Jan.…

4 weeks ago

Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan.…

4 weeks ago

Vector Solutions Marks Firefighter Cancer Awareness Month with Expanded Training and Education

Sixth year of training and education support reinforces long-term commitment to firefighter healthTAMPA, Fla., Jan. 13, 2026 /PRNewswire/ -- In…

4 weeks ago

ScreenPoint Medical and Ferrum Health partner to offer Transpara Breast AI through Ferrum’s AI Governance Suite

SAN FRANCISCO and NIJMEGEN, Netherlands, Jan. 13, 2026 /PRNewswire/ -- Ferrum Health will offer Transpara solutions through its Model Hub,…

4 weeks ago

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects 

– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising…

4 weeks ago

Propanc Biopharma Provides Shareholder Update

CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma,…

4 weeks ago